Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomedical Innovation Meeting From Energy and Commerce Shows Possible Legislative Roadmap

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee solicits feedback on the 2012 PCAST report on propelling drug innovation as it looks to craft legislation to speed biomedical innovation – but nearly all topics have already been addressed by stakeholders.

You may also be interested in...



Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?

House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.

Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike

A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.

Recipe For Doubling Innovative Medicines Includes New Approval Pathway, FDA Management Changes

Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.

Topics

UsernamePublicRestriction

Register

PS077208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel